July JAAD: Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE AD5)

AAD's Dialogues in Dermatology - A podcast by American Academy of Dermatology

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

George Han MD, FAAD interviewed by Elisa Gallo, MD, FAAD